Literature DB >> 12135553

Expression and purification of catalytically active, non-toxic endopeptidase derivatives of Clostridium botulinum toxin type A.

John A Chaddock1, Michael H Herbert, Roger J Ling, Frances C G Alexander, Sarah J Fooks, Dean F Revell, Conrad P Quinn, Clifford C Shone, Keith A Foster.   

Abstract

Clostridium botulinum neurotoxin type A is a potently toxic protein of 150 kDa with specific endopeptidase activity for the SNARE protein SNAP-25. Proteolytic cleavage of BoNT/A with trypsin leads to removal of the C-terminal domain responsible for neuronal cell binding. Removal of this domain result in a catalytically active, non-cell-binding derivative termed LH(N)/A. We have developed a purification scheme to prepare LH(N)/A essentially free of contaminating BoNT/A. LH(N)/A prepared by this scheme retains full enzymatic activity, is stable in solution, and is of low toxicity as demonstrated in a mouse toxicity assay. In addition, LH(N)/A has minimal effect on release of neurotransmitter from a primary cell culture model. Both the mouse bioassay and in vitro release assay suggest BoNT/A is present at less than 1 in 10(6) molecules of LH(N)/A. This represents a significant improvement on previously reported figures for LH(N)/A, and also the light chain domain, previously purified from BoNT/A. To complement the preparation of LH(N)/A from holotoxin, DNA encoding LH(N)/A has been introduced into Escherichia coli to facilitate expression of recombinant product. Expression and purification parameters have been developed to enable isolation of soluble, stable endopeptidase with a toxicity profile enhanced on that of LH(N)/A purified from BoNT/A. The recombinant-derived material has been used to prepare antisera that neutralise a BoNT/A challenge. The production of essentially BoNT/A-free LH(N)/A by two different methods and the possibilities for exploitation are discussed.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12135553     DOI: 10.1016/s1046-5928(02)00002-5

Source DB:  PubMed          Journal:  Protein Expr Purif        ISSN: 1046-5928            Impact factor:   1.650


  19 in total

1.  Re-engineering the target specificity of Clostridial neurotoxins - a route to novel therapeutics.

Authors:  K A Foster; E J Adams; L Durose; C J Cruttwell; E Marks; C C Shone; J A Chaddock; C L Cox; C Heaton; J M Sutton; J Wayne; F C G Alexander; D F Rogers
Journal:  Neurotox Res       Date:  2006-04       Impact factor: 3.911

2.  Bivalent recombinant vaccine for botulinum neurotoxin types A and B based on a polypeptide comprising their effector and translocation domains that is protective against the predominant A and B subtypes.

Authors:  Clifford Shone; Heidi Agostini; Joanna Clancy; Mili Gu; Huei-Hsiung Yang; Yanfang Chu; Virginia Johnson; Makie Taal; Joanna McGlashan; John Brehm; Xiaomi Tong
Journal:  Infect Immun       Date:  2009-04-27       Impact factor: 3.441

3.  Expression and purification of recombinant TAT-BoNT/A(1-448) under denaturing and native conditions.

Authors:  Parvaneh Saffarian; Shahin Najar Peerayeh; Jafar Amani; Firooz Ebrahimi; Hamid Sedighianrad; Raheleh Halabian; Abbas Ali Imani Fooladi
Journal:  Bioengineered       Date:  2016-08-26       Impact factor: 3.269

4.  The C-terminal heavy-chain domain of botulinum neurotoxin a is not the only site that binds neurons, as the N-terminal heavy-chain domain also plays a very active role in toxin-cell binding and interactions.

Authors:  B Vijayalakshmi Ayyar; K Roger Aoki; M Zouhair Atassi
Journal:  Infect Immun       Date:  2015-01-26       Impact factor: 3.441

5.  Novel Native and Engineered Botulinum Neurotoxins.

Authors:  Lance Steward; Mitchell F Brin; Amy Brideau-Andersen
Journal:  Handb Exp Pharmacol       Date:  2021

6.  High Yield Preparation of Functionally Active Catalytic-Translocation Domain Module of Botulinum Neurotoxin Type A That Exhibits Uniquely Different Enzyme Kinetics.

Authors:  Harkiranpreet Kaur Dhaliwal; Nagarajan Thiruvanakarasu; Raj Kumar; Kruti Patel; Ghuncha Ambrin; Shouwei Cai; Bal Ram Singh
Journal:  Protein J       Date:  2017-12       Impact factor: 2.371

7.  Identification of a Botulinum Neurotoxin-like Toxin in a Commensal Strain of Enterococcus faecium.

Authors:  Sicai Zhang; Francois Lebreton; Michael J Mansfield; Shin-Ichiro Miyashita; Jie Zhang; Julia A Schwartzman; Liang Tao; Geoffrey Masuyer; Markel Martínez-Carranza; Pål Stenmark; Michael S Gilmore; Andrew C Doxey; Min Dong
Journal:  Cell Host Microbe       Date:  2018-01-27       Impact factor: 21.023

8.  Purification and Characterization of Recombinant Botulinum Neurotoxin Serotype FA, Also Known as Serotype H.

Authors:  Gavin Hackett; Kevin Moore; David Burgin; Fraser Hornby; Bryony Gray; Mark Elliott; Imran Mir; Matthew Beard
Journal:  Toxins (Basel)       Date:  2018-05-11       Impact factor: 4.546

9.  Recombinant derivatives of botulinum neurotoxin A engineered for trafficking studies and neuronal delivery.

Authors:  Philip A Band; Steven Blais; Thomas A Neubert; Timothy J Cardozo; Konstantin Ichtchenko
Journal:  Protein Expr Purif       Date:  2010-01-04       Impact factor: 1.650

Review 10.  Targeted secretion inhibitors-innovative protein therapeutics.

Authors:  Foster Keith; Chaddock John
Journal:  Toxins (Basel)       Date:  2010-12-03       Impact factor: 4.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.